News & Analysis on Clinical Trial Services & Contract Research And Development
Diabetics moved a step closer to having an alternative to injections for their insulin therapy yesterday, after a US Food and Drug Administration (FDA) advisory committee gave its backing to an inhaled formulation of the drug developed by Pfizer,...
Biotechnology firm, MorphoSys, have announced an agreement with pharmaceutical company Shionogi, in a deal that fits into MorphoSys' effort to expand geographically into the Japanese market - currently the second largest individual pharmaceutical...
US researchers think they may have solved the puzzle as to why p53 activity occurs in both the nucleus and cytoplasm during apoptosis. The discovery could form a basis in the development of new anti-cancer therapies that target protein p53's activities.
US biotechnology firm XOMA has granted Wyeth a non-exclusive, worldwide license for a technology used to make biologic drugs such as antibodies in bacteria instead of mammalian cells.
Generics manufacturer Andrx Corp has become the latest generic drugs manufacturer to fall foul of the US Food and Drug Administration (FDA) because of quality issues at a manufacturing plant.
Bayer Healthcare has selected InforSense technology for the development of its integrative analytics infrastructure on a deal that sees InforSense provide a workflow-based cheminformatics platform.